Hong Kong Positions Itself as Strategic Gateway for Biotech Entry into China’s Healthcare Market

Andy Wong, Head of Innovation and Technology at InvestHK, is highlighting Hong Kong’s role as a critical entry point for international biotech firms looking to access the expansive Chinese healthcare market. By leveraging its common law legal system, robust intellectual property protections, and strategic location, the city offers a stable environment for translating research into commercial success. This positioning is particularly significant for the healthcare and biotech sector as it provides a bridge for clinical development and capital raising within the Greater Bay Area.

Andy Wong, representing InvestHK, emphasizes that Hong Kong’s unique regulatory and legal framework makes it a strategic springboard for foreign healthcare companies. Unlike mainland China, Hong Kong operates under common law, which provides international developers with greater confidence regarding intellectual property protection. To further attract biotech innovation, the city offers a simplified tax regime with low headline rates and specific R&D incentives, such as a "patent box" that applies concessionary tax rates to profits generated from local IP.

A central component of Hong Kong’s biotech strategy is the "bench to bedside to boardroom" pipeline, which links research, clinical trials, and commercialization. The newly established Greater Bay Area International Clinical Trial Institute plays a pivotal role in this process by facilitating multicenter trials across both Hong Kong and the broader Greater Bay Area. Wong suggests that while early-stage phase one development often remains in a company’s home country, shifting phase two and phase three trials to Hong Kong and China can provide a significant strategic advantage in accessing the massive and fast-moving Chinese patient population.

Beyond clinical development, Hong Kong serves as a primary hub for connecting biotech firms with global capital markets. The city boasts deep IPO and secondary markets, supported by active local investors and a history of successful licensing deals between Chinese biotech firms and global partners. Wong notes that listing and fundraising in Hong Kong can significantly accelerate project timelines. As Western companies traditionally focused on US and European regulatory pathways look to diversify, Hong Kong offers a familiar yet strategically located environment to scale operations into the Chinese market without abandoning established strategies.